medin. However, in four of five patients with persisting moderate azotemia (C,, 1 I .8-42.5 ml/min/1.73 m2), subnormal growth continued despite relatively normalized serum somatomedin activity. Three of the four poorly growing azotemic patients had the highest average steroid dosages in the group (prednisolone > 9.1 mg/m2/24 hr) .
Speculation
If low serum somatomedin activity develops in the course of end stage renal disease in children, growth retardation may be the consequence. After renal transplantation normalization of serum somatomedin activity may be a necessary although not sufficient condition for the resumption of growth.
Growth retardation is characteristic of children with chronic renal insufficiency. The control of renal insufflciency by homotransplantation [3, 10, 12, 19, 22, 24, 28 , 411 has resulted in variable improvement of growth velocity. Many children resume growth at a rate less than that expected for their chronologic age [24] , and "catch-up growth" has been observed only rarely 110, 241. Impaired growth associated with uremia has been speculatively attributed to many causes including uremic toxicity, anemia, undernutrition, acidosis, and diminished renal concentrating ability. The factors which influence growth response to transplantation have not been clearly defined. In a recent report [24] , resumption of growth after transplantation was apparently not correlated with renal function, maintenance steroid dosage, pretransplant height, donor source of kidney, or histocompatibility typing. T h e present investigation has attempted to identify, in nine children, the influence of various endocrine and metabolic factors upon growth velocity after transplantation. Inasmuch as growth hormone-dependent somatomedin (sulfation factor) is believed to be a principal determinant of linear growth 15, 6, 14, 301, preand post-transplant serum somatomedin levels in our patients were of special interest. Nine male children, ranging in age from 7-16 years, received 10 transplants (Table I) . At the time of the study, the patients had survived between 9 months and 5 years after transplantation. All patients were receiving prednisolone and azathioprine maintenance therapy. One patient, DG, was studied twice because of a major decrease in growth and renal function which occurred some time after transplantation.
Materials and iMethods

Clinicul unrl Laboratory Procedures
All patients were admitted as necessary to T h e New York Hospital-Cornell Medical Center Clinical Research Center. Serial heights, measured with the Harpenden stadiometer, were plotted using tables of the State University of Iowa growth standards. Bone age was estimated according to the method of Greulich and Pyle [13] . Pubertal status was evaluated and staged according to the method of Tanner [36] . Post-transplant growth performance was analyzed for the 12-month period ending at the time of evaluation and was related to bone age rather than chronologic age, because bone age appears to be more fundamentally related to growth velocity and was severely retarded in the patients. Growth velocity for bone age was calculated as follows:
observed height gain (cm/year) GVBA ( % ) = expected height gain for bone age X 100.
Expected height gain for bone age was obtained from the data of Tanner et al. [37] which substitutes the observed bone age for chronologic age in Tanner's tables.
T h e normal range for GVBA was assumed to be the mean k 2 SD. I n the nine patients studied, growth velocity, renal function and immunosuppressive therapy did not vary significantly during the 12-month reference periods. Creatinine clearance, expressed as milliliters per minute per 1.73 m2, was calculated from the mean value of two serial 24-hr values for creatinine Somatomedin and growth after renal trin~plznt 165 in twine 2nd one fasting serum creatinine. Creatinine was determined by the standard picric acid method [17] . If the two values of 21-hr creatinine in urine were widely discrepant, the urine collections were repeated. Stimulation tests of plasma growth hormone response were performed in seven patients, using a sequential intravenous arginine-insulin protocol [27] : 5% arginine hydorchloride in a dose of 0.5 g/kg was infused over 30 min; alter 1 hr, this was followed by an intravenous injection of regular insulin, 0.1 U/kg. Adequate hypoglycemia was defined as a 50% decrease of sugar level in blood [27] . Plasma growth hormone was determined by radioim~nunoassay [l 11. Growth hormone response was considered normal if a plasma level of at least 5 ng/ml was observed at any time.
Plasma growth hormone levels were also determined during tlle glucose tolerance tests.
Serum somatomedin activity was determined by bioassay [39] . T h e index of precision for this bioassay ranged from 0.09-0.52 (mean 0.25). T h e in uitro uptake of 3"s-sulfate uptake by hypophysectomized rat costal cartilage was calculated as units per milliliter, where 1 U was equivalent to the activity of 1 ml of our laboratory reference serum obtained from 10 healthy adult males. Because the rib uptake of "S-sulfate is dependent upon isotope dilution in the total inorganic sulfate pool of the incubation mixture [8] , the abnormally high levels ol inorganic sulfate in uremic sera (up to 10 times normal) artifactually reduced observed rib 3%-sulfate uptake by as much as 30%. Therefore, the serum inorganic sulfate concentration as measured by the benzidine method [18] was taken into account in calculations of 3%-sulfate uptake during assays of uremic sera. Sera to be assayed for somatomedin activity were stored at -15" until the time of assay. All of the posttransplant sera were stored for less than 1 year before assay except one post-transplant serum from DG (study I ) , which was 4.5 years old. T h e pre-transplant sera were criteria of the American Diabetes Association. Thyroid function was evaluated by serum protein-bound iodine and 1311 thyroidal uptake. Adrenal androgen secretion was evaluated by the determination of 24-hr excretion of 17-ketosteroids in urine [26] . Plasma follicle-stimulating hormone and luteinizing hormone were determined by radioi~nmunoassay [32] . T h e average daily caloric intake was estimated by a dietician and expressed as percentage of recommended caloric intake, based upon the 1968 Recommended Dietary Allowances (RDA) for children of the same height [25] . After transplantation, all patients were on an unrestricted diet, and caloric intakes met or exceeded the recommended dietary allowances.
Detailed clinical and laboratory data are presented in Table I .
Renal Fzinction after Transplantation
After transplantation, four patients (GL, PI;, JC, and TW) had relatively normal renal function until the time of study, with creatinine clearances (C,,.) which ranged from 40.3-93.5 ml/min/1.73 m' . These patients received predni~olone dosages of 1.7-4.5 mg/m"24 hr. Four patients (NT, PC, SC, and RM) were in a state of chronic rejection of the renal homograft at the time of study and throughout the 12-month period preceding it. These patients had C,, from 11.8-42.2 ml/min/ 1.73 m< and received 4.0-20.0 mg prednisolone/m"24 hr. Patient DG had a biphasic response. For the first 2 years after transplant (phase I), C,, was over 70 ml/min/ 1.73 m? Thereafter, he entered his present phase of poor renal function (phase 11) with C,, of less than 30 ml/min/1.73 mz.
Growth Pe~fomzance aftel-Transplant stored for 3 months-5.5 years before assay. Specimens
As shown in Figures 1 and 2 , growth was markedly DG ( s t z l d~ and TW were stored for 5.5 years retarded in all children at the time of transplantation and Years, none the preand all, except RM, were at or below the 3rd percentile transplant sera were stored longer than 2.5 Years. *lfor height. After transplantation, absolute growth rate though ifle question of stability of serum somatomedin (centimeters per year) remained essentially unchanged has not yet been studied specifically, we have seen no in four patients (TW, SC, PC, and Rill) (Fig. 2) ; indefinitive decrease of activity of sera stored in the frocreased in four (GL, PF, HT, and JC) (Fig. 1) , and zen state for up to 2 years. All samples were assayed showed a biphasic response in DG (Fig. 1 ). simultaneously.
The GVBA after transplantation (Table I) was norOral glucose tolerance tests were performed in six pamal (88-103%) in four patients (PF, HT, JC, and TW); tients, using a glucose dose of 1.75 g/kg with a maxiabove normal (127%) in one (GL); subnormal in three mum of 100 g. Glucose intolerance was defined by the (SC, PC, and RM), and biphasic in DG in whom it was L i l I~I 
Endocrine Function
Thyroid 1311 uptake, protein-bound iodine, 17-ketosteroids in urine, and plasma follicle-stimulating hormone and luteinizing hormone were all within normal limits in all patients. Sexual development after transplant corresponded reasonably with observed bone age. Oral glucose tolerance was abnormal in two of the six patients studied, one of whom (RM) was azotemic and receiving high doses of prednisolone (12.5 mg/m2/24 hr) at the time, while the other (GL) had normal renal function (C,, 67.6 ml/min/1.73 m2) and was on low dose prednisolone (2.8 mg/m"24 hr).
Basal growth hormone levels were normal (<5 ng/ ml) in all patients except RM, in whom it was 13 ng/ ml. Peak growth hormone levels after arginine-insulin tolerance test were normal in patients tested except RM, in whom it was greatly elevated (73 ng/ml). During glucose tolerance testing no patient had a paradoxical elevation of plasma growth hormone, and most patients had suppression below basal growth hormone levels.
Sonzatomedin
Mean pretransplant serum somatomedin activity in units per milliliter ( I . 1 SD) in the nine uremic children was 0.39 ("-0.10) as compared with 1.03 (i 0.16) in eight healthy male children matched for bone age (Fig. 3) . After transplantation, somatomedin activity rose by at least 65920 in each child. T h e mean post-transplant somatomedin activity was 0.84 i . 0.15, not significantly different from the healthy control subjects. Post-transplant SM was not significantly correlated with C,, (r = 1-0.327; P > 0.1), which indicates that mild to moderate renal functional impairment has no substantial effect upon serum somatomedin. (Table IZ) A significant positive correlation was demonstrable between GVBA and serum somatomedin activity ( SD limits of serum somatomedin activity in normal children. velocities. I n the five subjects (HT, S L , DG (study 2), Creatinine -0.559 clearance -1 SM: serum somatomedin; GVBA: growth velocity for bone age.
Col-elation between G V B A and Other Variables
2 P < 0.05.
+0.702; P < 0.05) (Fig. 4a) . T h e GVBA was also significantly positively correlated with C,, (r = +0.749; P < 0.05) (Fig. 4b) . On the other hand, there was only a slight negative correlation (r = -0.57 1) between GVBA and predl~isolone dose (Fig. 4c) . T h e borderline significance of this correlation (0.05 < P < 0.1) was entirely dependent upon the inclusion of the three patients receiving the highest prednisolone dosages, two of whom also had the poorest renal function.
T h e effect of restoration of renal function upon growth should be considered in terms of a postulated growth hol.mone-somatomedin-end organ system. I t is now well established that growth hormone does not act directly on skeletal tissues, i.e., cartilage and bone, but rather via generation of somatomedin, a llormonal polypeptide in serum formerly called "sulfation factor" [5, 6, PC, and RM) with impaired renal function after transplantation, one patient (RM) had an abnormally elevated stimulated G H and an elevated basal growth hormone level, as previously described [42] . No patient had a paradoxical growth hormone response to glucose ingestion [31] . Assuming that our subjects had at least normal basal and stimulated growth hormo~le in the pre-transplant state of severe growth retardation, it seems probable that neither pre-transplant growth retardation nor the variable growth response to transplantation could be related to variations in growth hormone secretion.
On the other hand, the presence of low serum somatomedin levels in the pretransplant growth-retarded state and the close correlation of somatomedin levels with post-transplant growth velocity indicate a more direct relation of somatomedin to growth. Hall and Olin [16] found in growth hormone-treated hypopituitary dwarfs that both growth velocity ancl serum somatomedin activity rise. Although this does not necessarily mean that the rise in somatomedin activity is causative for the increase in growtll velocity, the possibility cannot be excluded. Because somatomedin is at present quantified only by bioassay in vitro, interference by uremic toxins with the somatomedin bioassay must be considered. Results of preliminary ultrafiltration studies in our laboratory throw doubt upon this possibility [40] . If there is no ultrafiltrable inhibitor of the bioassay system, the level of somatomedin bioactivity in azotemic serum would then be the resultant of active physiologic processes of generation and removal in the azotemic subject. Nothing is known as yet about the Sz~mma~y degradative fate of serum somatomedin. There is evidence for substantial somatomedin generation by the liver [21] , and also fragmentary data which suggests the presence of somatomedin in muscle [I51 and perhaps even kidney 1201. T h e latter site would be of special relevance in uremia. I n any case, it is as yet impossible to estimate the relative roles of synthesis and degradation in the regulation of serum somatomedin activity.
Some invetsigacors have attributed growth failure in chronic uremia to decreased caloric intake [33, 381 . Caloric intake of 70% or more of RDA [25] was considered to be compatible with resumption of growth [33] . Although the dietary intakes of our patients were not clearly defined before transplantation, after transplantation all patients in this series were on an unlimited diet providing at least 100% of RDA of caloric intake. T h e difference between growing and nongrowing children after transplantation therefore could not be explained by diet.
Regardless of the mechanisms whereby uremia can affect the metabolism of somatomedin, the data indicated that relative normalization of serum somatomedin occurred after renal transplantation, even when mild azotemia persisted (patienls SC, PC, and DG, phase I I ) . However, if azotemia persisted, the growth response remained poor i n spite of normalized somatomedin levels, which suggested peripheral antagonism of somatomedin action. This peripheral resistance to somatomedin may be partially related to steroid therapy, since three of the four patients with subnormal growth velocity (SC, PC, and RM) had the highest average steroid dosage levels (20.0, 9.1, and 12.5 mg/m2/24 hr, respectively). Growth retardation associated with high dosage steroid therapy has been well documented [2, 23, 29, 341 and steroidal inhibitory effects upon rat rib cartilage have been demonstrated.The in vivo uptake of radioactive sulfate by rat cartilage was inhibited when the animal was treated with large doses of hydrocortisone [4, 351. Likewise, the conversion by rat rib cartilage of (14C)proline to hydroxyproline was inhibited by cortisol in vitro at a level of 0.9 pg/ml [7] , a level which markedly exceeds physiologic concentrations. I t is therefore possible that steroid therapy, particularly in high dosage, can contribute to apparent peripheral resistance to somatomedin action, as observed in some of our azotemic patients. T h e mechanisms of such peripheral antagonism are presently as obscure as the mechanisms of somatomedin stimulation of cartilaginous proliferation and linear growth.
Serum somatomedin activity was markedly deficient in a group of children with end stage renal disease and growth retardation. Somatomedin rose toward normal after renal transplantation. Continued azotemia and/or high dosage steroid therapy apparently inhibit partially resumption of growth even when somatomedin activity was normalized. An estimate of the overall frequency of low somatomedin in the uremic syndrome will require additional data from uremic children without growth retardation and from uremic adults.
